BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

Two doses of a simple tuberculosis vaccination after surgery helps the immune system fight cancer cells and could greatly ...

Discover how a TB vaccine could revolutionise bladder cancer treatment. Find out more about this groundbreaking study.

The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Guérin) therapy: a retrospective observational study,” published in the ...

doxorubicin or pirarubicin), whether immediately after surgery or after 2 weeks' delay, had similar outcomes to those who did not. By contrast, the 35 patients who received intravesical BCG ...

The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S. shortages and provide an alternative source of BCG, a critical standard-of-care in bladder cancer Multiple urology centers ...

Investigators trained and validated a deep-learning AI model to identify patients with high-risk NMIBC unlikely to benefit from BCG. Artificial ... in The Journal of Urology.

ImmunityBio (IBRX) announced U.S. Urology Partners ... Calmette-Guerin rBCG to address the current shortage of TICE BCG in the U.S. “The shortage of BCG has real consequences, especially ...

“Constrained BCG supply has improved stewardship of a limited resource but has come at a high cost to our patients,” said Dr. Chad Reichard, Co-Director of Clinical Research, Urology of Indiana.

“I’m pleased U.S. Urology is at the forefront of offering rBCG and would like to thank ImmunityBio for their initiative to seek and secure authorization from the FDA for expanded ...